Omeros

I'm glad to finally hear from Karnak who agrees it is a shitty drug.
BTW Karnak, you rocket scientist, it's not an oncology drug, it's an ophthalmic drug.
There are some rules like gravity which can not be defied. Like making you a same person. Can never happen..

 

Hey Mr. Fund manager. Please let me know if you are interested in the PT opening at the local McDonalds?
You will look great in that paper hat.

 

INCREASE YOUR FREQUENCY AND LUNCHES PER WEEK. I WANT ONE SPEAKER PROGRAM PER MONTH. WITH ONLY DOCTORS HVPS

 

pretty interesting article from Aug 31

http://seekingalpha.com/article/3478056-watch-for-a-potential-50-percent-drop-in-omeros

 

What kind of dog and pony show is Omeros going to put on at the AAO Meeting?

 

Greg will do what he does Best Buy more thought leaders to use this useless product. Can you say whistleblower coming very soon

 

The product works. End of story.

 

It works but is not needed especially at the rediculous cost! The only doctors using this product are those on the payroll.

 

That may be true in your area. I personally know many cataract surgeons that use Omidria in the hospital setting purely for its efficacy.

 

Purely for efficacy? LMAO!!!

 

TRy selling to hospitals instead of ASC's my friend, just trying to help. It is much different, reimbursed 80/20 at ASC's and 106% at hospitals. Best wishes and it helps when used with all the cataract surgeries instead of cherry picking when to use. Many docs say it has saved them from using rings.

 

The Omidria drug launch has been a failure.

 

See you at $6.00. The company needs to raise cash quickly and the pipeline is nothing but a pipe dream.

 

Omidria launched in April, 7 months ago, still a new drug on the market and hardly a time go call it over or a failure. Yes, there are hurdles to jump. It is imperative to keep attention on the goal and not put your attention on what you fear or others negative attacks. This is a product that works and if it was free everyone would be using it. Observing surgeries with this product is wonderful to see it helping surgeons during cataract surgery, especially new cataract surgeons just getting out there doing surgery.

 

Revision of Cataract Extraction Supplemental Instructions Article (A52819)

The Supplemental Instructions Article (SIA) listed below will be published January 1, 2016. The changes noted below will be effective January 1, 2016.

Cataract Extraction - Supplemental Instructions Article (A52819)

HCPCS code C9447 Injection, phenylephrine and ketorolac, 4 ml vial was added to the CPT/HCPCS Code Noncovered section of the article, effective for services rendered on or after January 1, 2016.



The article may be accessed under the "Future" article index on the Medicare Coverage Database before January 1, 2016.

• Omidria® is a sterile solution concentrate containing 1% w/v of phenylephrine and 0.3% w/v ketorolac in a single-patient-use vial.
• Omidria® is added to an ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

National Government Services considers the use of HCPCS code C9447- Injection, phenylephrine and ketorolac, 4 ml vial to be not separately payable when used in conjunction with cataract surgery or intraocular lens replacement.

Effective for services rendered on or after January 1, 2016, HCPCS code C9447 will be automatically denied as not separately payable when used during cataract surgery or intraocular lens replacement and submitted in conjunction with the following CPT codes: 66820, 66821, 66825, 66840, 66850, 66852, 66920, 66930, 66940, 66982, 66983, 66984, 66985, 66986.

 

translation please?

 

From this article it looks like CMS will not pay for Omidria in 2016? Is this true?

 

https://www.ngsmedicare.com/ngs/portal/ngsmedicare/newngs/home-lob/news-alerts/news-articles/news-detail/revision%20of%20cataract%20extraction%20supplemental%20instructions%20article%20(a52819)/!ut/p/a1/vVJNU8IwEP0r5eCMHjpJaZH2GD5E5BuHgfbCLCGFSJt22gjir3eLOOIB0RnHXJK3ebv7si8kIDMSKNjKFWiZKIgKHNzOHdZuWladdgbuPaWs02AO67dsd2KRKQlIkMNW8CTZSFEgHgnIPuG42WoP-ocLpVO9Jr5a5bFYSg4ZZiktlFZid0VPwu9Y7HIT1NKESGQ6_whkWmIHhMfcK5qJrcxRr5GEBgcNGXBtiBdd7EU4f07TSMTIhciQKtfZ8-EiN47FjGuolF3LuylUplwuiQ8cPM-qVs2KzaumY3ueCQ6eBOdLeyFC4YRuwe4OasQfYh2jhsPycVj0zGL0R7P8QrEHLmXOXa3RGA3tVq18JHzTwkcN1bNNLIs8FjWm9d58NGmOkX3iHaJT7xAevcPT6Tt_N6QLiuz_V_RwyQg0spz16r0VlgW9NqUKEzL7w282RcndNt37jKTxZtxy7dic0adKumKN1zCOGRv2zWCxZ6XSG2s4b8M!/dl5/d5/L2dBISEvZ0FBIS9nQSEh/?clearcookie=&savecookie=&REGION=&LOB=Part%20B

 

If the analyst get a hold of this yikes! If this is true it's time to look for a new job.